HIGHLIGHTS
- who: Hsin-Yu Kuo et al. from the Department of Internal Medicine, National Kung University Hospital, College of Medicine, National Kung University, Tainan, Taiwan have published the paper: Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma, in the Journal: (JOURNAL)
- what: The aims of this study were to investigate the differences in efficacy and safety between nivolumab and pembrolizumab in unresectable HCC patients in a setting. In this study, study, participants participants received received aa standard standard dose dose of of 33 mg/kg mg/kg of intravenous intravenous . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.